CureVac (NASDAQ:CVAC) Stock Price Down 7.2% – What’s Next?

Shares of CureVac (NASDAQ:CVAC) fell 7.2% during trading on Monday . The company traded as low as $2.72 and last traded at $2.77. 244,698 shares were traded during trading, a decline of 70% from the average session volume of 816,234 shares. The stock had previously closed at $2.98.

Wall Street Analysts Forecast Growth

Separately, JMP Securities restated a “market outperform” rating and set a $16.00 target price on shares of CureVac in a research report on Friday, February 14th.

CureVac Trading Down 1.8 %

The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. The business has a 50-day moving average price of $3.32 and a two-hundred day moving average price of $3.18. The firm has a market cap of $608.95 million, a PE ratio of 4.95 and a beta of 2.53.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets acquired a new stake in CureVac during the 4th quarter valued at $585,000. Two Sigma Investments LP purchased a new stake in shares of CureVac in the fourth quarter valued at $391,000. Alyeska Investment Group L.P. boosted its stake in shares of CureVac by 25.0% during the fourth quarter. Alyeska Investment Group L.P. now owns 500,000 shares of the company’s stock valued at $1,705,000 after acquiring an additional 100,000 shares during the last quarter. Jane Street Group LLC lifted its holdings in CureVac by 239.0% in the 3rd quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock valued at $235,000 after purchasing an additional 55,867 shares in the last quarter. Finally, Northern Trust Corp raised its position in shares of CureVac by 98.1% in the fourth quarter. Northern Trust Corp now owns 60,100 shares of the company’s stock valued at $205,000 after buying an additional 29,759 shares during the last quarter. 17.26% of the stock is owned by hedge funds and other institutional investors.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.